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ABSTRACT
Despite multimodal treatments comprising, radiation therapy (RT) and 
chemotherapy with temozolomide (TMZ), the prognosis of glioblastoma multiforme 
(GBM) remains dismal and consolidated therapy yields a median survival of 14.6 
months.
Blood Brain Barrier (BBB) mediated chemoresistance and high dose related toxicity 
make necessary the development of new therapeutic approach to sensitize GBM to TMZ.
The aim of the present study was to investigate the potential of the treatment 
morphine plus TMZ metronmic doses (1,77 and 0,9 mg/kg) in GBM therapy.
The effect of morphine, on tumor cell growth and P-glycoprothein (P-gp) activity, 
was investigate in in vitro models.
The results demonstrated that GBM cells growth is not influenced by morphine 
treatment and, for the first time, we show that morphine is an inhibitor of the activity 
of P-gp efflux transporter who is markedly expressed on BBB.
In vivo, response to the treatments TMZ plus morphine was investigated in an 
orthotopic nude mice model of GBM.
Animals treated with TMZ metronomic doses showed a significant tumor growth 
inhibition compared to untreated mice and association with morphine appears to 
improve TMZ efficacy.
Moreover, the combination of morphine with lower dose of TMZ result in a 
cytostatic effect on tumor growth over the period of the pharmacological treatments.
In conclusion this novel approach could be a successful strategy to overcome 
chemoresistance and side effects TMZ mediated, reducing drug dosage and improving 
long term response, in GBM therapy.
INTRODUCTION
GBM is the most common and aggressive primary 
brain tumor derived from glial progenitors of the central 
nervous system (CNS) [1, 2].
TMZ, the current standard care for GBM 
[3, 4], shows chemoresistance shortly after the initiation 
of treatment [5]; patients median survival is about 
12–18 months and only 3 % survive longer than 5 years 
[6].
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Resistance to TMZ has shown to be multifactorial, 
including changes in the cell cycle, up regulation of 
mismatch repair genes and MGMT [7] and additional 
TMZ resistance mechanisms involving P-gp expression, 
modulation and activity have been recently reported [8, 
9, 10].
P-gp belongs to the ATP binding cassette (ABC) 
transporters and plays the major role in the failure of 
cancer therapy, limiting the accumulation of a wide range 
of molecules in numerous tissue including the brain [11].
Different studies have shown that brain 
concentrations of TMZ are only 17–20 % of the blood 
levels [12, 13] and TMZ’s dose limiting toxicity of 
leukopenia and thrombocytopenia, with a possible 
increased risk of opportunistic infections, precludes the 
use of higher doses which theoretically could result in 
higher intratumoral concentrations.
It was also reported that antitumor activity of TMZ 
is highly schedule-dependent [14, 15]; many experimental 
and preclinical studies suggested that in vivo frequent 
administration of low doses of chemotherapeutic drugs, 
known as metronomic chemotherapy, could affect tumor 
endothelium and inhibit tumor angiogenesis, reducing 
significant side effects [16].
Basing on literature data regarding the 
pharmacological modulation of BBB by morphine [17], 
the most commonly used opioid in oncological patients, 
we have recently demonstrated that this agent is able to 
increase delivery and efficacy of doxorubicin (Dox) in 
animal models, without increasing systemic toxicities [18, 
19, 20, 21].
However, results about the effect of morphine on 
tumor cells are numerous and often controversial.
Some authors reported that morphine can reduce 
the efficacy of chemotherapy, stimulating tumor cell 
growth in brain, breast and renal cancer [22, 23, 24, 25]. 
Other reported that the association of morphine with 
chemotherapeutic agents result in an improved antitumor 
effect and suppression of cancer cells proliferation [26, 27]
Considering all this findings, the aim of the present 
study was further investigate the effect of morphine 
on tumor cells and explore the potential of combined 
treatments morphine plus TMZ in GBM therapy, in order 
to overcome chemoresistance and side effects TMZ 
mediated.
RESULTS
Effect of morphine on GBM cells proliferation
We tested the modulatory action of morphine on 
tumor cells growth treating two human GBM cell lines 
(U87MG and A172) with different doses of morphine (10, 
20, 40 μM) for 24 and 48 hours.
As show in Figure 1, no difference in cell 
proliferation, at 24 hours, can be observed comparing 
control groups and morphine treated groups, in both cell 
lines. Data were confirmed comparing treated groups vs 
control groups after 48 hours of treatment, in both cell 
lines.
Effect of morphine on ATPase activity of P-gp
The drug efflux function of P-gp is coupled to ATP 
hydrolysis, which is stimulated in the presence of P-gp 
substrates.
Our data indicated that the ATP concentration 
measured in samples treated with different concentration 
of morphine are significantly higher compared to 
Verapamil samples (*p< 0,01) (Figure 2A), indicating that 
in presence of morphine there was a reduced consumption 
of ATP.
To assess the effect of morphine on the P-gp ATPase 
activity, P-gp-mediated ATP hydrolysis was measured, 
with the appropriate formula reported in materials and 
method section, using ATP concentration of morphine and 
sodium orthovanadate samples. As shown in Figure 2B, 
all morphine doses are able to reduce the ATPase activity 
of P-gp.
Effect of combined treatment TMZ plus 
morphine on tumor growth in glioblastoma 
xenograft
Basing on literature data reporting that TMZ 
metronomic administrations are more effective than a 
single bolus dose [14], a preliminary experiment was 
realized to evaluate TMZ concentration for treatments.
Animals were treated daily with TMZ (1,77-2,66 
and 4 mg/kg) for five weeks and tumor growth was 
monitored trough weekly BLI acquisition.
Data shown in Figure 3 revealed that all TMZ doses 
were effective in tumor growth inhibition compared to 
control (p<0,05) so 1,77 mg/kg, the lowest concentration 
that achieved a significant results, were chosen as dosage 
for next experiments.
The first step experiment was then performed 
combining TMZ treatment (1,77 mg/kg) with morphine 
(10 mg/kg) [16-20].
One week after tumor implantation, animals were 
divided in four groups and treated following the first 
step experiment’s schedule as described in materials and 
methods section. Time-course and bioluminescence (BLI) 
evaluation of tumor growth are reported in Figure 4.
Statistical significant results were obtained 
comparing BLI data of treated groups vs control group, 
at days +28, +35 and +42. At day +28 the BLI Average 
Radiance of control group was 2,81E+05 vs 3,67E+04 
of TMZ group (**p<0,01) and 2,97E+04 of TMZ plus 
morphine group (**p<0,01). BLI Average Radiance of 
control group, at day +35, was 8,71E+05 vs 3,68E+04 
of TMZ group (***p<0,001) and 2,58E+04 of TMZ plus 
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Figure 1: Effect of morphine on human GBM cells growth. U87MG and A172 cells were treated with various concentrations of 
morphine for 24 and 48 hours. No changes in cell growth can be observed comparing controls vs all morphine dosages, in both cell lines 
and times. Data were expressed as mean ± SD.
Figure 2: Interaction between morphine and P-gp ATPase activity. (A) After 40 min of incubation with various concentrations 
of morphine, the remaining unmetabolized ATP was detected as a luciferase-generated luminescent signal. Statistical differences can be 
observed comparing ATP concentration of Verapamil vs all doses of TC (*p<0,01). Data were expressed as mean ± SD. (B) ATP consumption 
reflected P-gp ATPase activity. In presence of morphine the function of the efflux transporter was lower than NT and Verapamil, indicating 
that morphine is a functional inhibitor of P-gp. Data were expressed as mean ± SD.
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morphine group (***p<0,001). On the last BLI acquisition, 
day +42, the Average Radiance of control group was 
1,10E+06 vs 4,70E+04 of TMZ group (**p<0,01) and 
1,95E+04 of TMZ plus morphine group (**p<0,01) (Figure 
5). At day +42 two animals of control group died before 
BLI acquisition.
This data indicated that TMZ metronomic 
treatments have significant effect, from day +28 to day 
+42, on tumor growth but, analyzing the global trends of 
tumor regression, the BLI Average Radiance of TMZ plus 
morphine group was 2.5 fold lower than value observed 
in TMZ group (Figure 6). No differences in body weight 
loss were observed comparing control group vs all treated 
groups (Figure 7).
Effect of morphine in combination with lower 
dose of TMZ
We also investigated if combined treatment with 
morphine could make possible further reduction of TMZ 
dose, preserving the therapeutically effect of the alkylating 
agent.
To test this hypothesis, the second step experiment 
was performed comparing the effect of an half dose of 
TMZ (0,9 mg/kg), with or without morphine, vs TMZ 
(1,77 mg/kg).
One week after tumor implantation, animals were 
divided in four groups and treated following the second 
step experiment’s schedule as described in materials and 
methods section.
Statistical significant results were obtained 
comparing BLI data of treated groups and control group 
at the end of the treatments (day +42).
The BLI Average Radiance of control group was 
4,55E+05 vs 1,12E+04 of TMZ (1,77 mg/kg) group 
(****p<0,0001), 5,51E+04 of TMZ (0,9 mg/kg) group 
(***p<0,001) and 6,98E+04 of TMZ (0,9 mg/kg) plus 
morphine group (****p<0,0001) (Figure 8A).
At the end of the treatments (day +42), TMZ (1.77 
mg/kg) determined a tumor volume inhibition (TVI%, 
reported as BLI reduction and calculated comparing BLI 
value with BLI of control group treated with vehicle only) 
of 97,5%; meanwhile, TMZ (0,9 mg/kg), alone or in 
combination with morphine, determined a TVI between 
84% (TMZ 0,9 mg/kg plus morphine) and 88% (TMZ 0,9 
mg/kg), without significant difference between the two 
groups. No differences in body weight loss were observed 
comparing control group vs all treated groups (Figure 8B).
Figure 3: BLI average radiance throughout the experimental time. Statistical significant differences were observed comparing 
BLI Averageradiance of control group vs all TMZ treated groups (p<0,05). Physiological solution 5 ml/kg (violet line), TMZ 1,77 mg/kg 
(blue line), TMZ 2,66 mg/kg (red line), and TMZ 4 mg/kg (green line). Data were expressed as mean ± SD.
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Figure 4: BLI average radiance curves distinctly for group of treatment and days of treatment. Atday +42, morphine 
treatment (red) is not associated with an increased tumor growth compared to control group (black) while statistically significant differences 
(**p<0,01) were found between vehicle group vs TMZ 1,77 mg/kg group (green) and TMZ 1,77 mg/kg plus morphine 10 mg/kg group 
(blue). Data were expressed as mean ± SD.
Figure 5: Therapeutically effect of TMZ metronomic treatments. TMZ 1,77 mg/kg, whit or without morphine, is effective 
in tumor growth inhibition from early administration and not only at the end of the experiment as cumulative doses effect. Statistical 
analysis wasperformed, at day +28,+35 and +42, between vehicle group (black), TMZ 1,77 mg/kg group (green) and TMZ 1,77 mg/kg plus 
morphine 10 mg/kg group (blue) (**p<0,01, ***p<0,001). Data were expressed as mean ± SD.
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Combined treatment with morphine increases 
long-term response to TMZ
Long-term response to the treatments was evaluated 
from day +42, end of treatments, until day +84 (all animals 
were sacrified) (Figure 9A).
At the end of the treatments, TMZ (1.77 mg/kg) 
showed a TVI of 97,5%; this inhibition persists for the 
whole experimental period and reaches up to over 100% 
(day +84).
Figure 6: BLI average radiance curves distinctly for groups and days of treatment. TMZ (1,77 mg/kg) shows an important 
effect in combination with morphine (10 mg/kg), determining a BLI reduction of 2,5 fold compared to BLI measured in group treated with 
only TMZ (1,77 mg/kg). Data were expressed as mean ± SD.
Figure 7: Body weight evaluation throughout the experimental time. Side effects of treatments were evaluated in terms of body 
weight variation. No statistical significant differences were reported between all different groups, indicating that the improved antitumor 
activity of TMZ plus morphine treatment was not associate to an increased systemic toxicity. Data were expressed as mean ± SD.
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The combination TMZ 0,9 mg/kg plus morphine 
maintained a more or less stable reduction after the end 
of the treatments until the day +84 with a TVI of 97,3% 
while, the effect of TMZ 0.9 mg/kg alone ended after 
the end of treatments (TVI from 88% to 79%, day +42 
and +84 respectively). In accordance, the BLI Average 
Radiance of TMZ 0,9 mg/kg plus morphine group was 7.8 
fold lower than value measured in group treated with only 
TMZ 0.9 mg/kg (Figure 9B) and, at day +84, statistical 
significant difference were observed comparing BLI data 
of co-treated group vs control group (*p<0,05) (Figure 9C).
As control, animals were treated with morphine 
alone; in this case morphine administration does not 
determine any tumor volume variation compared 
to animals treated with the vehicle at the end of the 
treatments (day +42). Conversely, we found a 90,7% of 
TVI at day +84, but we have to underline that this effect 
could be due to the lower number of animals survived in 
this group.
DISCUSSION
Currently adjuvant treatment of GBM is based on 
the association of RT and TMZ administrations [3].
However, chemoresistance and TMZ-induced 
side effects (anemia, lymphopenia, neutropenia, severe 
thrombocytopenia [3, 28, 29, 30] and liver injury [31, 
32]) represent a big challenge in the management of 
oncological patients.
The development of combination therapy that 
could sensitize GBM to TMZ is essential so, the aim 
of the present study was investigate the potential of an 
innovative combinational approach with morphine to 
improve chemotherapy effectiveness, reducing drug 
dosage and consequently TMZ-induced side effects.
Morphine is the most used drug for the pain 
management in oncological patients but, literature data 
regarding the effect of the opioid agent on tumor cells 
growth are numerous and controversial [22, 23, 24, 25, 26]
Figure 8: BLI signals throughout the experimental time. (A) Statistical analysis was performed between vehicle and the 
other experimental groups (****p<0,0001; ***p<0,001). Data were expressed as mean ± SD. (B) Side effects of treatments were 
evaluated in terms of body weight variation. No statistical significant difference were reported between all different groups. 
Data were expressed as mean ± SD.
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On the other hand, in vivo studies have suggested 
that stress associated with high doses morphine 
administration or withdrawal can influence the BBB 
function [17, 33, 34] and allow the accumulation and the 
efficacy of anticancer drugs [21].
Judging from all these facts, we first investigated 
the effect of morphine treatments on GBM tumor cells 
growth. Our in vitro results showed that exposure to 
micromolar concentrations of morphine not influenced 
cells growth (Figure 1), indicating that this agent don’t 
represent a proliferative stimulus for the tested GBM cells.
To well understand the molecular mechanism 
underlying the effect of morphine on BBB permeability, 
we have further investigated the possible interaction 
between the opioid agent and the efflux protein P-gp, 
overexpressed in the endothelial cells of the BBB and 
involved in resistance to many chemotherapeutic drugs.
For the first time, our in vitro results demonstrated 
that morphine is an effective P-gp inibhitor (Figure 2B), 
suggesting that the opioid agent could enhances the 
effects of chemotherapeutic drugs in brain tissue through 
reduction of the ATP binding cassette transporter function.
Based on the in vitro data acquired in this study and 
experimental and clinical literature suggesting a key role 
for P-gp in GBM resistance to TMZ [8, 9], we determined 
to evaluate the efficacy of combination of morphine with 
TMZ metronomic treatment in an in vivo model of GBM.
First step experiment data have indicated that 
morphine treatment is not associated with an increased 
tumor growth compared to control group (Figure 4) and 
Figure 9: Long-term response to TMZ. (A) Images of BLI acquisition of Group 4 (TZM 0,9 mg/kg) and Group 5 (TZM 0,9 mg/kg 
plus morphine) of the Second Step Experiment, at day +42 (end of treatment) and day+ 84 (sacrifice). BLI is expressed as a total radiance 
in photons per sec/cm2 per steradian. The colorimetric scale represents the range of radiance values (red=highest value; blu=lowest value) 
which translates to tumor growth. (B) BLI Average radiance curves distinctly for group of treatment and days of treatment. TMZ (0,9 
mg/kg) shows an important effect in combination with morphine (10 mg/kg), determining a BLI reduction of 7,8 fold compared to BLI 
measured in group treated with only TMZ (0,9 mg/kg). Data were expressed as mean ± SD. (C) Comparison of TMZ (0,9 mg/kg) alone or 
in combination with morphine (10 mg/kg) at day +84 vs vehicle, showed a significant reduction of BLI of combination TMZ (0,9 mg/kg) 
plus morphine (10 mg/kg) (*p<0,05) while TMZ (0,9 mg/kg) is not statistically significant. Data were expressed as mean ± SD.
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also that TMZ 1.77mg/kg metronomic treatment, with or 
without morphine, is effective in tumor growth inhibition 
from early administrations and not only at the end of the 
experiment as cumulative doses effect (Figure 5).
However, analyzing the global trend of tumor 
regression it was possible to appreciate the important 
effect that TMZ showed in combination with morphine. 
At day +42, the BLI Average Radiance of TMZ plus 
morphine group was 2.5 fold lower than value measured 
in group treated with only TMZ (Figure 6). Moreover, this 
improvement in antitumor activity of TMZ plus morphine 
treatment was not associate to an increased systemic 
toxicity, evaluated as difference in body weight loss 
between co-treated group and all other groups (Figure 7).
This data encouraged us to test if the combination 
with morphine could make possible a further reduction 
of TMZ dosage, with additional benefits in terms of side 
effects.
Co-treatment with TMZ (1,77 and 0,9 mg/kg), 
with or without morphine, determined an important 
tumor growth inhibition, TMZ (1,77 mg/kg) showed a 
TVI of 97,5% meanwhile, TMZ (0,9 mg/kg), alone or in 
combination with morphine, determined a tumor reduction 
between 84% and 88%.
Moreover, from day +42 until day +84, we observed 
that while the effect of the half dose of TMZ alone ended 
after the end of treatments, the combination of half dose 
of TMZ plus morphine maintained a more or less stable 
reduction from the end of the treatments until the day +84, 
with a TVI of 97,3%.
As reported in Figure 9B, BLI values of TMZ 0.9 
mg/kg, with or without morphine, started from the same 
point (day+42) but, while BLI values of TMZ 0.9 mg/kg 
group increased, the BLI values of TMZ 0.9 mg/kg plus 
morphine group remained stable over the time reaching, 
at day +84, a BLI fold decrease of 7.8 compared to TMZ 
0.9 mg/kg group.
The cytostatic effect of the co-treatment was 
further supported comparing BLI values of this group 
vs control group. In Figure 9B can be observed that both 
treatments curves are below the control but, at the end 
of the experiment, there was a statistical significant 
difference (*p<0,05) in tumor volumes only between 
control and TMZ 0.9 mg/kg plus morphine groups 
(Figure 9C).
In conclusion, our results demonstrated that 
morphine is a P-gp inhibitor, TMZ metronomic treatment 
are effective in GBM therapy and also that combination 
TMZ plus morphine shows an increased effectiveness in 
tumor growth inhibition and long term response in a GBM 
xenograft model.
More study are necessary to well understand the 
appropriate schedule of co-treatment but, this safe and 
non-invasive approach could be a successful strategy 




Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the authors’ 
institutional review board.
Drugs and reagents
TMZ (Sigma Aldrich) dissolved in sterile H2O was 
administered, at different concentrations, per os (p.o.) in 
a volume of 5 ml/kg. Morphine (Molteni & C s.p.a.) 10 
mg/kg was dissolved in sterile saline and subcutaneously 
(sc) administered in a volume of 5 ml/kg. All chemicals 
and solvents were of the highest purity available from 
commercial sources and used without further purification.
MTT assay
The effect of morphine on tumor cells growth was 
measured using the MTT assay (in vitro toxicology assay 
kit MTT based, Sigma). The key component of this assay 
is (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium 
bromide), a yellow salt that mitochondrial dehydrogenases 
of viable cells convert into purple formazan crystals, 
whose concentration is measured spectrophotometrically. 
We have conducted preliminary experiments to determine 
the best seeding concentration for U87MG and A172 cells. 
Consequently, cells were seeded at the following densities: 
A172, 6x104 cells/well and U87MG, 4x104 cells/well 
in 24-well plates. After 24 hours, the cells were treated 
morphine 10, 20 and 40 μM for 24 and 48 hours. The 
MTT assay was performed following the manufacturer’s 
instructions. The plates were placed on a shaker for 10 
minutes to enhance solubilization of the precipitate. 
The absorbance of each well was then measured on a 
MULTISKAN FC (Thermo Scientific) microplate reader 
at a test wavelength of 550 nm. All experiments were 
performed tree times in triplicate
Adenosine triphosphatase (ATPase) assay of 
P-gp
The ATPase activities of P-gp were determined 
using the luminescent ATP detection kit (Pgp-Glo Assay 
Systems, Promega, Madison, WI) according to the 
manufacturer’s instructions. Briefly, 1.25 mg/mL P-gp 
membranes and 25 mM MgATP were incubated in absence 
or presence of morphine, at 37 °C for 40 minutes. The 
relative lights units (RLU), representing the luciferase-
generated luminescent signal, were detected on a plate-
reading luminometer (The GloMax® 96 Microplate 
Luminometer, Promega).
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RLU of each sample was interpolate with RLU of 
ATP standards to obtain ATP concentrations in control 
(NT) and test compounds (TC). The impact of TC on 
P-gp ATPase activity was examined comparing NT and 
samples treated with different concentrations of morphine 
to Na3VO4 (sodium orthovanadate)-treated control 
and Verapamil-treated control, that are respectively an 
inhibitor and a stimulator of the P-gp activity.
Basal P-gp ATPase activities were determined as 




([ATP ] [ATP ])
(25 g P gp x 40 minutes)
Na3VO4 NT
Verapamil and morphine-stimulated P-gp 




([ATP ] [ATP ])
(25 g P gp x 40 minutes)
Na3VO4 TC
All experiments were performed two times in 
triplicate.
Animals
A total of 136 Foxn1 nude mice have been used in 
this study. The procedure of animals accommodation and 
care have been described in detail previously [21].
Briefly, 6- to 7-weeks-old nude female mice Foxn1, 
weighing approximately 21-28 g, were housed inside 
polysulfone cages (4-5 mice/cage) with stainless steel 
cover-feed and sterilized and dust-free bedding cobs. 
Mice were maintained in cages with paper filter covers; 
food and bedding were sterilized. All manipulations 
were carried out according to the European Community 
guidelines for animal care (DL 116/92, application of 
the European Communities Council Directive 86/609/
EEC). Animals were inspected throughout experiments 
for mortality. Physical appearance, behaviour, general 
and local clinical signs were also observed; all efforts 
were made to minimize animal sufferings and mice 
showing clinical signs of pain and distress were sacrificed 
for humane reasons by CO2 inhalation. At the end of 
experiments, all mice were sacrificed by CO2 inhalation.
Tumor implantation
U87MG-luc2 (PerkinElmer Italia S.P.A., Monza, 
Italy), a human GBM cell line stably transfected with 
firefly luciferase gene (luc2), was used to establish the 
orthotopic glioma model.
Cells were cultured in Eagle’s Minimum Essential 
Medium containing heat-inactivated FBS at final 
concentration 10% and maintained in a humidified 
atmosphere of 5% CO2-95% air at 37°C. On the day of the 
tumor implantation mice were micro-injected with 3x105 
U87MG-luc2 cells, suspended in 5 μl of saline solution, 
in the left lobe of brain with infusion of 1 μl/min (with 
Hamilton syringe).
Following intracranial tumor injection, BLI 
acquisitions were performed, at day 0, 3 and 7, for baseline 
data.
Experimental design
After tumor implantation (day +7), mice were sorted 
on the basis of BLI Average Radiance and randomly 
allocated as follows.
Pilot experiment:
Group 1 (Ctr): naïve mice received physiological 
solution (5 ml/kg). Group 2 (TMZ 1,77 mg/kg): daily 
administrations from day 7 to 37. Group 3 (TMZ 2,66 
mg/kg): daily administrations from day 7 to 37. Group 4 
(TMZ 4 mg/kg): daily administrations from day 7 to 37.
Each experimental group contained 7 animals. 
Tumor growth and weight were carried out weekly and 
biweekly respectively, for five weeks.
First step experiment:
Group 1 (Ctr): naïve mice received physiological 
solution (5 ml/kg).
Group 2 (morphine): morphine weekly 
administrations (days 7, 14, 21, 28, 35).
Group 3 (TMZ 1,77mg/kg): TMZ daily 
administrations from day 7 to 42.
Group 4 (TMZ 1,77 mg/kg+morphine): weekly 
administrations of morphine and daily administrations of 
TMZ.
Each experimental group contained 10 animals. 
Tumor growth and weight were carried out weekly and 
biweekly respectively, for five weeks.
Second step experiment:
Group 1 (Ctr): naïve mice received physiological 
solution (5 ml/kg).
Group 2 (morphine): morphine weekly 
administrations (days 7, 14, 21, 28, 35). Group 3 (TMZ 
1,77 mg/kg): TMZ daily administrations from day 7 to 42.
Group 4 (TMZ 0,9 mg/kg): daily administrations of 
TMZ from day 7 to 42.
Group 5 (TMZ 0,9 mg/kg+morphine): weekly 
administrations of morphine and daily administrations of 
TMZ.
Each experimental group contained 10 animals. 
Tumor growth and weight were carried out weekly and 
biweekly respectively, for five weeks. Animals of each 
groups were observed from day +42 (end of treatments) 
until the day +84 for long-term response evaluation.
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Bioluminescence acquisition
Tumor growth and response to the treatments were 
monitored by BLI acquisitions, using IVIS 200 Spectrum 
Imaging System (PerkinElmer). BLI acquisitions were 
performed at day 0, 3, 7 and then weekly until the end of 
experiments.
In detail, mice were i.p. administered with 150 
mg/kg/10 mL of Dluciferin (PerkinElmer, Xenolight 
D-Luciferin Potassium Salt, 1g, #122799, batch 
K9906PE, stored at -20°C) and, 30 minutes upon luciferin 
administration, were anesthetized by gas anesthesia 
(3% isoflurane for induction, 1.5% for maintaining). All 
animals were placed into the IVIS 200 Imaging System 
to be imaged. BLI was expressed as Average Radiance in 
photons per sec/cm2 per steradian.
Body weight
Body weight (BW) variation was calculated as 
follows: [(actual BW (g) x 100) / initial BW (g)] – 100. 
Measurements were carried out biweekly and, as humane 
endpoint, animals showing a BW reduction ≥ 15% were 
sacrificed by CO2 inhalation.
Statistical analysis
Data were expressed as mean ± SD. Statistical 
analyses were performed using U-Test between two groups 
while comparison between multiple groups were performed 
using 1 or 2 way ANOVA followed by post hoc corrections, 
as appropriate. All analyses were done using GraphPad 
Prism 5 and P<0,05 was considered statistically significant.
ACKNOWLEDGMENTS
We are grateful to Tommaso Mello, Ph.D., 
University of Florence, Italy, for his skillful technical 
assistance.
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of 
interest.
FUNDING
This work was supported by: Associazione Italiana 
per la Ricerca sul Cancro (AIRC), grant IG–12799, 
“Amicodivalerio” Onlus, “Noi per Voi” Onlus and 
Fondazione Tommasino Bacciotti Onlus.
REFERENCES
1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel 
JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, 
Chin L, DePinho RA, Cavenee WK. Malignant astrocytic 
glioma: genetics, biology, and paths to treatment. Genes 
Dev. 2007; 21: 2683-2710.
2. Louis DN. Molecular pathology of malignant gliomas. 
Annu Rev Pathol. 2006; 1: 97-117.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher 
B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, 
Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, 
et al. Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. N Engl J Med. 2005; 352: 
987-996.
4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn 
MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger 
K, Hau P, Brandes AA, Gijtenbeek J, et al. Effects of 
radiotherapy with concomitant and adjuvant temozolomide 
versus radiotherapy alone on survival in glioblastoma in a 
randomised phase III study: 5-year analysis of the EORTC-
NCIC trial. Lancet Oncol. 2009; 10: 459-466.
5. Friedman HS, Kerby T, Calvert H. Temozolomide and 
treatment of malignant glioma. Clin Cancer Res. 2000; 6: 
2585-2597.
6. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, 
Rosenfeld M, Fisher J, Consortium NC. Survival of patients 
with newly diagnosed glioblastoma treated with radiation 
and temozolomide in research studies in the United States. 
Clin Cancer Res. 2010; 16: 2443-2449.
7. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet 
N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani 
L, Bromberg JE, Hau P, Mirimanoff RO, et al. MGMT gene 
silencing and benefit from temozolomide in glioblastoma. 
N Engl J Med. 2005; 352: 997-1003.
8. Munoz JL, Walker ND, Scotto KW, Rameshwar P. 
Temozolomide competes for P-glycoprotein and contributes 
to chemoresistance in glioblastoma cells. Cancer Lett. 2015; 
367: 69-75.
9. Munoz JL, Rodriguez-Cruz V, Greco SJ, Nagula V, Scotto 
KW, Rameshwar P. Temozolomide induces the production 
of epidermal growth factor to regulate MDR1 expression in 
glioblastoma cells. Mol Cancer Ther. 2014; 13: 2399-2411.
10. Schaich M, Kestel L, Pfirrmann M, Robel K, Illmer T, 
Kramer M, Dill C, Ehninger G, Schackert G, Krex D. A 
MDR1 (ABCB1) gene single nucleotide polymorphism 
predicts outcome of temozolomide treatment in 
glioblastoma patients. Ann Oncol. 2009; 20: 175-181.
11. Loscher W, Potschka H. Role of drug efflux transporters 
in the brain for drug disposition and treatment of brain 
diseases. Prog Neurobiol. 2005; 76: 22-76.
12. Portnow J, Badie B, Chen M, Liu A, Blanchard S, Synold 
TW. The neuropharmacokinetics of temozolomide in 
patients with resectable brain tumors: potential implications 
for the current approach to chemoradiation. Clin Cancer 
Res. 2009; 15: 7092-7098.
13. Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, 
Decosterd LA, Stupp R. Plasma and cerebrospinal fluid 
Oncotarget89606www.impactjournals.com/oncotarget
population pharmacokinetics of temozolomide in malignant 
glioma patients. Clin Cancer Res. 2004; 10: 3728-3736.
14. Kim JT, Kim JS, Ko KW, Kong DS, Kang CM, Kim MH, 
Son MJ, Song HS, Shin HJ, Lee DS, Eoh W, Nam DH. 
Metronomic treatment of temozolomide inhibits tumor cell 
growth through reduction of angiogenesis and augmentation 
of apoptosis in orthotopic models of gliomas. Oncol Rep. 
2006; 16: 33-39.
15. Kong DS, Lee JI, Kim WS, Son MJ, Lim DH, Kim ST, Park 
K, Kim JH, Eoh W, Nam DH. A pilot study of metronomic 
temozolomide treatment in patients with recurrent 
temozolomide-refractory glioblastoma. Oncol Rep. 2006; 
16: 1117-1121.
16. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate 
KH, Augustin HG. Heterogeneity of angiogenesis and 
blood vessel maturation in human tumors: implications 
for antiangiogenic tumor therapies. Cancer Res. 2000; 60: 
1388-1393.
17. Sharma HS, Ali SF. Alterations in blood-brain barrier 
function by morphine and methamphetamine. Ann N Y 
Acad Sci. 2006; 1074: 198-224. https://doi.org/10.1196/
annals.1369.020.
18. Sardi I, la Marca G, Cardellicchio S, Giunti L, Malvagia 
S, Genitori L, Massimino M, de Martino M, Giovannini 
MG. Pharmacological modulation of blood-brain barrier 
increases permeability of doxorubicin into the rat brain. Am 
J Cancer Res. 2013; 3: 424-432.
19. Sardi I, la Marca G, Giovannini MG, Malvagia S, Guerrini 
R, Genitori L, Massimino M, Arico M. Detection of 
doxorubicin hydrochloride accumulation in the rat brain 
after morphine treatment by mass spectrometry. Cancer 
Chemother Pharmacol. 2011; 67: 1333-1340.
20. Sardi I. Morphine facilitates doxorubicin penetration in the 
central nervous system: a new prospect for therapy of brain 
tumors. J Neurooncol. 2011; 104: 619-620.
21. da Ros M, Iorio AL, Consolante D, Cardile F, Muratori 
M, Fantappie O, Lucchesi M, Guidi M, Pisano C, Sardi 
I. Morphine modulates doxorubicin uptake and improves 
efficacy of chemotherapy in an intracranial xenograft 
model of human glioblastoma. Am J Cancer Res. 2016; 6: 
639-648.
22. Amini-Khoei H, Hosseini MJ, Momeny M, Rahimi-Balaei 
M, Amiri S, Haj-Mirzaian A, Khedri M, Jahanabadi S, 
Mohammadi-Asl A, Mehr SE, Dehpour AR. Morphine 
attenuated the cytotoxicity induced by arsenic trioxide in 
H9c2 cardiomyocytes. Biol Trace Elem Res. 2016; 173: 
132-139.
23. Cao LH, Li HT, Lin WQ, Tan HY, Xie L, Zhong ZJ, 
Zhou JH. Morphine, a potential antagonist of cisplatin 
cytotoxicity, inhibits cisplatin-induced apoptosis and 
suppression of tumor growth in nasopharyngeal carcinoma 
xenografts. Sci Rep. 2016; 6: 18706.
24. Lazarczyk M, Matyja E, Lipkowski AW. A comparative 
study of morphine stimulation and biphalin inhibition 
of human glioblastoma T98G cell proliferation in vitro. 
Peptides. 2010; 31: 1606-1612.
25. Bimonte S, Barbieri A, Rea D, Palma G, Luciano A, Cuomo 
A, Arra C, Izzo F. Morphine promotes tumor angiogenesis 
and increases breast cancer progression. Biomed Res Int. 
2015; 2015: 161508.
26. Ge ZH, Wang ZX, Yu TL, Yang N, Sun Y, Hao CL, Sun LX. 
Morphine improved the antitumor effects on MCF-7 cells 
in combination with 5-Fluorouracil. Biomed Pharmacother. 
2014; 68: 299-305.
27. Kim JY, Ahn HJ, Kim JK, Kim J, Lee SH, Chae HB. 
Morphine suppresses lung cancer cell proliferation through 
the interaction with opioid growth factor receptor: an in 
vitro and human lung tissue study. Anesth Analg. 2016; 
123: 1429-1436.
28. Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia 
T, Bahr O, Meyermann R, Bamberg M, Tatagiba M, von 
Deimling A, Weller M, Wick W. Chemoradiotherapy 
of newly diagnosed glioblastoma with intensified 
temozolomide. Int J Radiat Oncol Biol Phys. 2010; 77: 
670-676.
29. Niewald M, Berdel C, Fleckenstein J, Licht N, Ketter R, 
Rube C. Toxicity after radiochemotherapy for glioblastoma 
using temozolomide--a retrospective evaluation. Radiat 
Oncol. 2011; 6: 141.
30. Dixit S, Baker L, Walmsley V, Hingorani M. 
Temozolomide-related idiosyncratic and other uncommon 
toxicities: a systematic review. Anticancer Drugs. 2012; 23: 
1099-1106.
31. Grieco A, Tafuri MA, Biolato M, Diletto B, Di Napoli 
N, Balducci N, Vecchio FM, Miele L. Severe cholestatic 
hepatitis due to temozolomide: an adverse drug effect to 
keep in mind. Case report and review of literature. Medicine 
(Baltimore). 2015; 94: e476.
32. Aygun C, Altinok AY, Cakir A, Agan AF, Balaban Y. 
Acute temozolomide induced liver injury: mixed type 
hepatocellular and cholestatic toxicity. Acta Gastroenterol 
Belg. 2016; 79: 487-489.
33. Sharma HS, Sjoquist PO, Ali SF. Alterations in blood-brain 
barrier function and brain pathology by morphine in the 
rat. Neuroprotective effects of antioxidant H-290/51. Acta 
Neurochir Suppl. 2010; 106: 61-66.
34. Afsharimani B, Cabot P, Parat MO. Morphine and tumor 
growth and metastasis. Cancer Metastasis Rev. 2011; 30: 
225-238.
